Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study

Kim, T. H.; You, Hyun Wook; Park, J. H.; Lee, J. G.; Choo, Min Soo; Park, W. H.; Lee, J. Z.; Park, C. H.; Na, Yong Gil; Kwon, Dongdeuk; Lee, K.-S.

doi:10.1111/ijcp.12783

Cited by 13 publications

(7 citation statements)

References 25 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we found that 45.4% patients discontinued the FDC medication within 6 months. This finding was similar to that in previous Korean studies evaluating treatments for other urologic conditions, including LUTS/BPH and overactive bladder [15][16][17]. However, this finding was much lower than that in previous western studies evaluating treatment persistence with once-daily tadalafil for ED [18].…”

Section: Discussionsupporting

confidence: 87%

Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction

et al. 2020

View full text Add to dashboard Cite

The primary aim of this study was to assess treatment persistence with a fixed-dose combination (FDC) of tadalafil (5 mg) and tamsulosin (0.4 mg). This study also evaluated the reasons for early treatment discontinuation. Materials and Methods: This retrospective observational study included patients with benign prostatic hyperplasia and erectile dysfunction who started an FDC treatment of tadalafil (5 mg) and tamsulosin (0.4 mg) between July 2017 and February 2018. Treatment persistence and reasons for early discontinuation were evaluated during the first 6 months. The cumulative discontinuation rate and differences in various parameters were assessed using Kaplan-Meier analysis and the log-rank test, respectively. Factors related to persistence were analyzed using a Cox proportional hazard model. Results: Overall, 97 patients were included in the study. The cumulative persistence rate at 30, 90, and 180 days was 88.7%, 66.0%, and 54.6%, respectively. The cumulative persistence over 6 months differed significantly according to the administration of FDC therapy (log-rank p=0.005) and age (log-rank p=0.024). Younger patients (odds ratio, 2.049; p=0.021) and treatment-naive patients (odds ratio, 2.461; p=0.006) were more likely to discontinue therapy within 6 months. The common reasons for discontinuing therapy were side effects (63.6%) and perceived poor efficacy (22.7%). Conclusions: Side effects were reported to be the main reason for treatment discontinuation. Thus, to improve compliance for a once-daily FDC of tadalafil (5 mg) and tamsulosin (0.4 mg), it is recommended to select patients who show adaptation to a combination of α-blockers and phosphodiesterase type 5 inhibitors prior to FDC treatment.

show abstract

Section: Discussionsupporting

confidence: 87%

Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Lee et al [ 53 ] reported that only 25% of men with benign prostatic obstruction and OAB remained on their solifenacin add-on therapy after tamsulosin monotherapy within one year in a real clinical environment. Kim et al [ 54 ] also reported that 1-year persistence on solifenacin was 22.1% in a prospective, multicenter, observational study conducted in Korea. In their study, persistence at 12, 24, and 36 weeks was 72.4%, 45.8%, and 31.1%, respectively.…”

Section: Persistence and Compliance Among Patients Receiving Pharmacomentioning

confidence: 99%

“…In a postal-based survey conducted in the United States, 24.5% of patients who had been prescribed antimuscarinics for OAB reported that they had discontinued one or more antimuscarinic prescription medications during the previous 12 months [ 29 ]. In other open-label observational studies, the rates of medication discontinuation in 12 months were 21% to 78% of those taking antimuscarinics [ 27 51 52 53 54 ]. In a multicenter, prospective, and observational study conducted in Korea [ 27 ], 56.8% of patients with OAB remained on their antimuscarinics at 24 weeks.…”

Section: Persistence and Compliance Among Patients Receiving Pharmacomentioning

confidence: 99%

“…On the other hand, 44% of patients taking either long-acting tolterodine extended-release and oxybutynin extendedrelease persisted with the medication for longer than 30 days. Several studies have found that older patients are more likely than younger patients to persist in taking OAB pharmacotherapy [ 27 47 49 54 58 ]. Female sex also can be a risk factor for discontinuation of OAB pharmacotherapy [ 54 58 ].…”

Section: Improving Persistence With Pharmacological Treatment For Oabmentioning

confidence: 99%

See 1 more Smart Citation

Persistence and compliance with medication management in the treatment of overactive bladder

Kim

Lee

2016

Investig Clin Urol

View full text Add to dashboard Cite

Overactive bladder (OAB) is a common and chronic condition that impacts patients' daily activities and quality of life. Pharmaco-therapy for OAB is a mainstay of treatment. Antimuscarinics and β3-adrenoceptor agonists are the two major classes of oral pharmacotherapy and have similar efficacy for treating the symptoms of OAB. Owing to the chronic nature of OAB, long-term use of medication is essential for OAB symptom control and positive health outcomes. However, many patients elect to stop their medications during the treatment period. Unmet expectations of treatment and side effects seem to be the major factors for discontinuing OAB pharmacotherapy. Furthermore, the short- and long-term persistence and compliance with medication management are markedly worse in OAB than in other chronic medical conditions. Improvement in persistence and compliance with OAB pharmacotherapy is a hot topic in OAB treatment and should be an important goal in the treatment of OAB. Effective strategies should be identified to improve persistence and compliance. In this review, we outline what is known about persistence and compliance and the factors affecting persistence with pharmacotherapy in patients with OAB.

show abstract

“…Those studies that included persistence for at least one of the treatments evaluated in table or graph form were selected. 8,12,[20][21][22][23][24][25][26][27][28][29][30][31] We did a multiple comparison treatment from real world evidence persistence studies. The results were weighted according to the sample size for each treatment, taking into account the time frame for each study.…”

Section: Probabilitiesmentioning

confidence: 99%

Clinical and Economic Evaluation of Transdermal Oxybutynin in the Treatment of Overactive Bladder in Spain

Crespo¹,

Blasco

Guigini

et al. 2018

JHEOR

View full text Add to dashboard Cite

Background: This study evaluated the clinical outcomes and economic results of transdermal oxybutynin compared to fesoterodine, tolterodine, solifenacin, oxybutynin, trospium chloride, and mirabegron for overactive bladder syndrome in Spain. Materials and Methods:A Markov model was built with monthly cycles for a 5-year time frame. The model reflected clinical events, discontinuation, dose scaling and change in treatment according to actual clinical practice. Based on experts' opinion and the literature, the use of resources and Spanish costs were incorporated into the model. The measure of efficiency used was the cost per quality-adjusted life year (QALY) gained. The economic evaluation was performed from the perspective of the Spanish healthcare system, discounting costs (€2017) and effects at 3%. The robustness of the results was validated with a deterministic and probabilistic sensitivity analysis. Results:After a year, transdermal oxybutynin was seen to have greater persistence deriving from its better risk/benefit balance compared to muscarinic antagonists and mirabegron (55% transdermal oxybutynin, 33% mirabegron, 25% tolterodine, 27% fesoterodine, 25% solifenacin, 23% trospium chloride and 17% oxybutynin). At 5-years, better persistence resulted in improvements in QALY gained by transdermal oxybutynin of 0.050, 0.040, 0.039, 0.038, 0.034 and 0.010 compared to oxybutynin, fesoterodine, solifenacin, trospium chloride, tolterodine and mirabegron, respectively. The incremental cost-effectiveness ratio of transdermal oxybutynin ranged from €1313.96 per QALY gained compared to fesoterodine to €14 101.57 per QALY gained compared to trospium chloride. Conclusions: Kentera ® (transdermal oxybutynin) is a cost-effective treatment in overactive bladder syndrome compared to muscarinic antagonists and mirabegron. Keywords: idiopathic overactive bladder, oxybutynin transdermal patch, cost-effectiveness, persistence, mirabegron, oral muscarinic antagonists JHEOR Crespo C, et al. 195 JHEOR 2018;5(2):194-205 | www.jheor.org BACKGROUND Disease BurdenOveractive bladder (OAB) syndrome is defined by the presence of urinary urgency, with or without urge urinary incontinence (UUI), often accompanied by urinary frequency and nocturia. 1 It is estimated that there are approximately 1.5 million people with OAB in Spain 2 ; however, only 16.7% of patients with OAB receive treatment. 3 OAB has a significant negative impact on the quality of life (QoL) of patients, their family members and their caregivers, since it affects social function, sexual function, interpersonal relationships and work life. 1,4 In addition, UUI has been associated with an increase in the use of resources and a decrease in the productive capacity of working-age patients. 5,6 Crespo C, et al. 203JHEOR 2018;5(2):194-205 | www.jheor.org information on the use of resources and costs. Thus, an estimate with real cost and effectiveness data could be prepared. CONCLUSIONSOXY-TDS led to more QALYs gained, due to its persistence and tolerability, and was a highly cost...

show abstract

Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study

Abstract: There was low persistence (22%) to solifenacin therapy for OAB symptoms over a 12-month period. Older patients, female patients and those with fewer episodes of nocturia were more persistent to therapy than were others.

Cited by 13 publications

References 25 publications

Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction

Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction

Persistence and compliance with medication management in the treatment of overactive bladder

Clinical and Economic Evaluation of Transdermal Oxybutynin in the Treatment of Overactive Bladder in Spain

Contact Info

Product

Resources

About